Evidence map›Paper›PMID 30108831›Full record

ArticleMedChemComm2017

Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities.

Ji Liu, Tingting Wang, Xinyang Wang, Lin Luo, Jing Guo, Yanfu Peng, Qibing Xu, Jiefei Miao, Yanan Zhang, Yong Ling

Open access · bronzeAbstract read
In one paragraph

Article in MedChemComm, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Novel Hybrid CHC from β-carboline andFrontiers in pharmacology · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Ji LiuSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Tingting WangSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Xinyang WangSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Lin LuoSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Jing GuoSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Yanfu PengSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Qibing XuSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Jiefei MiaoSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Yanan ZhangSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.
Yong LingSchool of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target , Nantong University , Nantong 226001 , P.R. China . Email: zhangyanan@gmail.com ; Email: Lyyy111@sina.com.ORCID 0000-0002-3373-011X
Nantong University · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of novel β-carboline-based hydroxamate derivatives (

Identifiers

PMID30108831
PMCPMC6071927
OpenAlexW2602864929

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.